Related Experiment Video
Updated: Jun 5, 2026
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
Dose-toxicity models in oncology
Michel Adamina1, Markus Joerger
1Cantonal Hospital St. Gallen, Department of Surgery, Rorschacherstrasse 95, 9007 St. Gallen, Switzerland. michel.adamina@gmail.com
Introduction:
The first human exposure to a new medicine always carries a major risk. Assessment of the safety profile and determination of a therapeutic dose are formidable tasks, particularly in oncology where toxicity is seen as a surrogate for efficacy. Increasing evidence supports the adoption of innovative dose-toxicity models, as these are safer and more efficient in meeting the challenges of modern investigational oncology than traditional models used in Phase I clinical trials.
Areas Covered:
A literature review on dose-toxicity models in oncology was carried out. The objective of this study was to provide a non-mathematical, reader-friendly overview of current and innovative dose-toxicity models in oncology with an emphasis on recent clinical advances, including the benefits of a Bayesian framework.
Expert Opinion:
Innovative dose-toxicity models attempt to minimize clinical risk and maximize research performance. Of these, the Bayesian Continual Reassessment Method and the Escalation With Overdose Control are two successful contemporary designs that outperformed traditional models in clinical trials; they account for patient heterogeneity, combination therapy, and they appropriately assess molecularly targeted agents. Support by regulatory authorities is providing an additional incentive to the widespread use of innovative and efficient dose-toxicity designs: this will improve investigational oncology, and ultimately benefit patients and science alike.
Insights
Innovative dose-toxicity models enhance oncology drug development by minimizing patient risk and improving efficiency. Bayesian Continual Reassessment Method and Escalation With Overdose Control show superior performance over traditional Phase I trial designs.
Area of Science:
- Oncology
- Clinical Pharmacology
- Biostatistics
Background:
- Determining safe and effective doses for new oncology drugs is challenging.
- Traditional Phase I clinical trial models face limitations in managing toxicity and efficacy.
- Innovative dose-toxicity models offer safer and more efficient approaches.
Purpose of the Study:
- To provide a non-mathematical overview of dose-toxicity models in oncology.
- To highlight recent clinical advances and the benefits of Bayesian frameworks.
- To compare innovative models with traditional methods in Phase I trials.
Main Methods:
- Literature review of dose-toxicity models in oncology.
- Focus on current and innovative designs.
- Emphasis on Bayesian approaches and recent clinical applications.
Main Results:
- Innovative models, such as Bayesian Continual Reassessment Method and Escalation With Overdose Control, outperform traditional designs.
- These models effectively handle patient heterogeneity and combination therapies.
- They are suitable for assessing molecularly targeted agents.
Conclusions:
- Innovative dose-toxicity models reduce clinical risk and enhance research efficiency.
- Regulatory support encourages the adoption of these advanced designs.
- Widespread use will advance investigational oncology and benefit patients.
Related Concept Videos
01:21Dose Response Curve: Conventional Versus Nonmonotonic
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
01:27Pharmacodynamic Models: Overview
01:09Pharmacodynamic Models: Additive and Proportional Drug Effect Model
01:21Toxicokinetics: Overview
01:24Drug Toxicity: Dose-Dependent Reactions